News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
![InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025](https://www.innoserlaboratories.com/wp-content/uploads/2025/03/ADPD-2025-InnoSer-Neurodegenerative-Disease-Models-400x250.png)
InnoSer Presents New Data on Tau[P301S] and α-Synuclein Combination Models for Neurodegenerative Research at ADPD 2025
We are excited to announce that InnoSer, as an innovative European preclinical neurodegenerative disease CRO, will be actively participating in the upcoming ADPD 2025 conference, taking place in Vienna, Austria from 1st to 5th April 2025. The ADPD 2025 Conference is...
Top 4 Multi-Organ-on-a-Chip TissUse Assays and Why You Should Include them in Your Preclinical Research in 2025
Preclinical research is evolving rapidly, and staying ahead means embracing innovative tools that streamline processes and provide actionable insights. Multi-Organ-on Chip (MOC) assays, also known as microphysiological systems (MPS), are among the most exciting...
InnoSer Strengthens Neurology Platform with Acquisition of remynd’s CRO Business
InnoSer’s acquisition of remynd’s CRO business further strengthens its neurology platform by integrating specialized neurodegenerative mouse models, expanding its service portfolio for Alzheimer’s and Parkinson’s diseases. Diepenbeek, Belgium – March 4th – InnoSer, a...
Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research
The Meso-Scale Discovery (MSD) platform is a high-sensitivity, multiplex cytokine profiling analysis system, enabling you to simultaneously quantify multiple target cytokines, chemokines, antibodies, and growth factors from minute sample volumes (as low as 1 µL). By...
Targeted Gene Therapy Preclinical Testing Approaches in the ADPKD Mouse Model
With several recent gene therapy approvals in space and more on the horizon, the field of rare genetic diseases is experiencing a transformative era. The field of rare genetic kidney diseases, including ADPKD remains no exception to this, with gene therapy emerging as...
Gene Therapy Delivery Strategies: Helping You Address Challenges for CNS Diseases
With several recent gene therapy approvals in the CNS space and more on the horizon, the field of both genetic and neurodegenerative diseases is experiencing a transformative era. However, translating these therapies from preclinical research to clinical application...
How to Advance your Preclinical Research Using Mouse Data to Establish PK/PD Relationships
The major objective of early drug development is to select the most promising compounds and establish safe and effective doses and dosing regimens. To do so, an analysis of both the pharmacokinetic (PK) and pharmacodynamic (PD) properties of your novel compound needs...
InnoSer International Announces Leadership Transition: Kris Motmans Appointed as New CEO
Diepenbeek, Belgium, Feb 17, 2025 — InnoSer International, a leading preclinical Contract Research Organization (CRO) specializing in innovative solutions for drug development, proudly announces the appointment of Kris Motmans as the new Chief Executive Officer. This...
MDX Mouse Model Validation Data
This month we’re highlighting one of the most commonly used mouse models to study Duchenne Muscular Dystrophy (DMD) – the MDX mouse model B10.mdx), and explore how our advanced services can support your efficacy studies in DMD. The X-linked muscular dystrophy (MDX)...
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Project Completion Announcement: CARDIOIDS Collaboration with Professor Leon de Windt Advances Arrhythmogenic Cardiomyopathy (ACM) Research
In its role as an industry research partner, InnoSer is pleased to announce the successful completion of the CARDIOIDS project, a consortium-led initiative led by Professor Leon de Windt at Maastricht University. This project represents a major milestone in...
InnoSer and TissUse Sign Strategic Co-Marketing Agreement to Advance Microphysiological Systems (MPS) Applications in Drug Development
InnoSer, a leading preclinical contract research organization (CRO), and TissUse, a pioneer in the field of microphysiological systems (MPS) development, are pleased to announce the signing of a strategic co-marketing agreement aimed at promoting the widespread...
info@innoserlaboratories.com